Worth Venture Partners, LLC Prothena Corp Public LTD CO Call Options Transaction History

Worth Venture Partners, LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2018 Aug 13, 2018	SELL	$10.99 - $44.21 $192,325 - $773,675	-17,500 Closed	0 $0
Q1 2018 May 25, 2018	SELL	$27.95 - $45.04 $48.4 Million - $78 Million	-1,732,500 Reduced 99.0%	17,500 $184,000
Q1 2018 May 11, 2018	BUY	$27.95 - $45.04 $48.6 Million - $78.2 Million	1,737,200 Added 13571.88%	1,750,000 $184,000
Q4 2017 Feb 14, 2018	BUY	$35.44 - $63.76 $453,632 - $816,128	12,800	12,800 $111,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $641M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Worth Venture Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Worth Venture Partners, LLC with notifications on news.